A 2021 "Hack Week" idea led us to a new approach for gathering #data from #cells using #brightfield - a 17th century technique w/ powerful new possibilities thanks to #ml. Since brightfield does not perturb cells, scientists can examine multiple layers of biology on the same

Since our earliest days, we’ve planned a sunrise hike to the top of #Utah’s Mt. Olympus, led by co-founder and CEO Chris Gibson. It begins in the wee hours of the morning, in darkness. The reward is a new perspective & shared connection with nature & one another. This year,

Announcing positive Phase 2 topline results for our first-in-disease treatment for cerebral cavernous malformation (#CCM) – the #AI drug discovery that launched our company. REC-994 met its primary endpoint of safety & tolerability & showed promising MRI-based secondary efficacy

Exciting results for our patients. We are proud to have participated Penn Medicine Penn Neurosurgery Penn Stroke and Cerebrovascular Surgery with the highest patient enrollment in the trial #cavernousmalformation #ccm Recursion Visish M. Srinivasan, MD Joshua Catapano

So much attention has been paid to improving & accelerating discovery – but what about the clinical side? At the Drug Discovery Innovation Forum (#DDIF) in Berlin Sept. 4-5, Karen Sayal, MB BChir, MRCP, FRCR, DPhil, will present on how we are applying our automated workflows to